N
QNCX icon

Natixis’s Quince Therapeutics QNCX Stock Holding History

Natixis’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-31
Closed -$306K – 1095
2020
Q3 		$306K Sell
31
-30
-49% -$273K ﹤0.01% 658
2020
Q2 		$564K Sell
61
-22
-27% -$202K ﹤0.01% 601
2020
Q1 		$757K Buy
83
+23
+38% +$227K 0.01% 519
2019
Q4 		$674K Sell
60
-3
-5% -$18.1K ﹤0.01% 684
2019
Q3 		$315K Buy
+63
New +$388K ﹤0.01% 723

Other funds holding QNCX

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SUT
SC US (TTGP) Menlo Park, California $9.25B AUM 20.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PHAM
Pacific Heights Asset Management San Francisco, California $2.99B AUM 52.5% 1-Year Est. Return

Natixis's QNCX Position: Q4 2020 in Review

Natixis sold out of Quince Therapeutics (QNCX) in Q4 2020, closing a stake of 31 shares — an estimated $306K sold.

Natixis first reported a position in QNCX in Q3 2019 and held it in 5 quarters. The position peaked at $757K in Q1 2020. 84 funds tracked by Wall St. Rank hold QNCX as of Q4 2020.

  • Natixis reported no remaining Quince Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Natixis sold 31 Quince Therapeutics shares in Q4 2020, an estimated $306K.
  • Natixis first reported a position in Quince Therapeutics in Q3 2019 and held it in 5 quarters.
  • Natixis's Quince Therapeutics position peaked at $757K in Q1 2020.
  • 84 funds tracked by Wall St. Rank held Quince Therapeutics as of Q4 2020.

Based on Natixis's 13F filing for Q4 2020, filed 12 Feb 2021.